Ovid Therapeutics (OVID) Net Cash Flow Growth (1y) (2017 - 2026)
Ovid Therapeutics (OVID) Net Cash Flow Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ovid Therapeutics | 118.66 Mn | -36.86 Mn | - | 1,668.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,668.89% |
| Dec 31, 2025 | -164.31% |
| Sep 30, 2025 | 47.14% |
| Jun 30, 2025 | 771.59% |
| Mar 31, 2025 | -238.47% |
| Dec 31, 2024 | 137.13% |
| Sep 30, 2024 | -3.45% |
| Jun 30, 2024 | -112.57% |
| Mar 31, 2024 | -79.49% |
| Dec 31, 2023 | -127.01% |
| Sep 30, 2023 | 2.52% |
| Jun 30, 2023 | 109.13% |
| Mar 31, 2023 | 186.06% |
| Dec 31, 2022 | -11.10% |
| Sep 30, 2022 | -40.13% |
| Jun 30, 2022 | -349.40% |
| Mar 31, 2022 | -113.12% |
| Dec 31, 2021 | 18.75% |
| Sep 30, 2021 | -122.77% |
| Jun 30, 2021 | -250.07% |